Disclosure Of Earnings Per Share [Text Block]

Innate Pharma - Filing #5981200

Concept 2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
Disclosure of earnings per share [text block]
Earnings per share [text block]
Earnings per share [abstract]
Earnings per share [line items]
Basic earnings per share [abstract]
Basic earnings (loss) per share from continuing operations
61.00
9.00
Basic earnings (loss) per share from discontinued operations
Basic earnings (loss) per share
61.00
9.00
Diluted earnings per share [abstract]
Diluted earnings (loss) per share from continuing operations
61.00
9.00
Diluted earnings (loss) per share from discontinued operations
Diluted earnings (loss) per share
61.00
9.00
Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract]
Weighted average number of ordinary shares used in calculating diluted earnings per share
81 051 798 xbrli:shares
80 453 282 xbrli:shares
Disclosure of depositary receipts [text block]
Disclosure of depositary receipts [abstract]
Disclosure of depositary receipts [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.